Polymyalgia Rheumatica Epidemiology

• Polymyalgia rheumatica is among the most common inflammatory rheumatic conditions in older adults, and is a major contributor to geriatric inflammatory disease burden, particularly in primary care and rheumatology settings. 
• There is marked ethnic and geographic variation, with higher incidence in Northern European populations and comparatively lower rates reported in Asian and African populations, supporting a role of genetic susceptibility and environmental factors. 
• Underdiagnosis in early disease stages, as symptoms overlap with other common conditions such as osteoarthritis and nonspecific musculoskeletal pain, leading to potential underestimation of true prevalence in routine clinical practice.

Polymyalgia Rheumatica Epidemiology Forecast in the 7MM

• 2025 Diagnosed Prevalent Cases of Polymyalgia Rheumatica: ~XX
• 2036 Projected Diagnosed Prevalent Cases of Polymyalgia Rheumatica: ~XX
• Polymyalgia Rheumatica Growth Rate (2026–2036): XX% CAGR

DelveInsight's ‘Polymyalgia Rheumatica – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the polymyalgia rheumatica, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Polymyalgia Rheumatica Understanding and Diagnosis Algorithm

Polymyalgia Rheumatica Overview

Polymyalgia rheumatica is a chronic inflammatory rheumatic disorder that primarily affects adults aged 50 years and older and is characterized by bilateral shoulder and hip pain, prolonged morning stiffness, and systemic inflammation. The condition can significantly impair mobility and quality of life and is frequently associated with giant cell arteritis, reflecting a shared inflammatory disease spectrum. Owing to its prevalence in older adults, risk of relapse, and dependence on long-term corticosteroid therapy, polymyalgia rheumatica represents a significant clinical burden.

Further details are provided in the report.

Polymyalgia Rheumatica Diagnosis

The diagnosis of polymyalgia rheumatica is primarily clinical and is based on characteristic symptoms, elevated inflammatory markers, and exclusion of alternative conditions. Patients typically present with bilateral shoulder pain, morning stiffness, and elevated erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP) levels. The 2012 EULAR/ACR classification criteria support disease classification and incorporate age ≥50 years, bilateral shoulder aching, and abnormal inflammatory markers as key components. Imaging modalities such as ultrasound, MRI, and PET/CT may be used to identify characteristic inflammatory changes and improve diagnostic confidence, particularly in atypical cases.

Further details are provided in the report.

Polymyalgia Rheumatica Epidemiology

Key Findings from Polymyalgia Rheumatica Epidemiological Analysis and Forecast 

• Polymyalgia rheumatica is predominantly a disease of older adults, with incidence increasing sharply after 50 years of age and peak onset typically between 70–80 years, while being rare below 50 years, confirming its strong association with ageing populations. 
• The highest disease burden is observed in individuals aged 70–80 years, with both incidence and prevalence rising significantly in older populations. 
• Women are affected more frequently than men, with female-to-male ratios typically ranging from 2:1 to 3:1.
• There is strong geographic variability, with significantly higher incidence in Northern European and Scandinavian populations compared to Southern Europe, suggesting a role of genetic and environmental susceptibility factors.                        

Scope of the Report

• The report covers a segment of a descriptive overview of polymyalgia rheumatica, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression. 

Report Insights

Polymyalgia Rheumatica Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of polymyalgia rheumatica? What will be the growth opportunities across the 7MM concerning the patient population with polymyalgia rheumatica?
• What is the historical and forecasted polymyalgia rheumatica patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives on the diagnostic challenges to overcome barriers in the future.
• Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.